Sable Bio

Sable Bio, a London-based AI drug safety startup, has successfully raised £2.8 million in seed funding, with MMC Ventures leading the investment round.

Summary of transaction details:

• Value: £2.8 million
• Sector: Healthcare & Biotech (AI Drug Safety)
• Advisor: Not mentioned
• Key Entities: Sable Bio (Target), MMC Ventures (Lead Investor)
• Location: London, UK

Note: This funding will be instrumental in scaling Sable Bio's platform, which aids pharmaceutical companies in identifying safety risks earlier in the drug discovery process, thereby improving efficiency and patient outcomes.